This article discusses advances in the diagnosis & treatment of Sjögren’s disease, as well as practical diagnostic tips for clinicians.
New FDA Label Requirements for Opioids
After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.
Preventive Strategies & Novel Treatments for RA
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
Why Advocacy Matters: A Call to Action for Rheumatologists
In today’s rapidly evolving healthcare landscape, rheumatologists face a growing number of challenges. Advocacy is a critical tool that helps protect and advance the profession and the patients it serves.
Include Advocacy in Your ACR Convergence 2025 Plans
Check out this quick guide to advocacy events and programming that will help you leave Chicago informed and ready to be an advocate for the rheumatology community back home.
Medical Liability Reform Position Statement Now Addresses Harmful Payer Policies, Telemedicine Authorization & Patient Compensation
The largest changes include additions that address harmful payer policies, telemedicine authorization and patient compensation funds.
UHC Formulary Change Impacts Coverage for Ustekinumab
Effective Sept. 1, the brand name drug Stelara will no longer be covered on the UnitedHealthcare commercial plan prescription drug list.
At Summer Meeting, Insurance Legislators Discuss Policies Impacting Rheumatology
The National Council of Insurance Legislators (NCOIL) 2025 Summer Meeting, held July 16–19 in Chicago, Ill., included discussion of several policy issues relevant to rheumatology.
What ASTP/ONC’s 2025 Regulations Mean for Rheumatologists
The ASTP/ONC’s recently updated United States Core Data for Interoperability Version 6 includes new data elements and applicable standards to support the provision of precision medicine and better patient care across the healthcare system.
Medicare Drug Price Negotiation: What ACR Members Need to Know Ahead of Round Three
As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 325
- Next Page »